Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Feature | Structural Heart Occluders | By Dave Fornell, Editor

FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

September 20, 2021

Videos | Congenital Heart

VIDEO: The Heart Team Approach in Congenital Structural Heart Interventions

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, explains the importance of the heart team ...

September 15, 2021

Non-invasive evaluation of heart valves using echocardiography first, and other cardiac imaging techniques when needed, is the key evaluation of heart valves in the new ESC and European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular heart disease. Photo by Dave Fornell.

News | Structural Heart

New European Guidelines on Valvular Heart Disease Published

September 13, 2021 — The European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery ...

September 13, 2021

Sponsored Content

As medical advancements continue to push the boundaries of what is possible in the field of structural heart interventions, the importance of enterprise imaging has become increasingly evident.

Blog | Enterprise Imaging

BLOG: The Power of Enterprise Imaging in Structural Heart Procedures

As medical advancements continue to push the boundaries of what is possible in the field of structural heart ...

August 10, 2023

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies

Edoxaban May Be Effective Treatment for Atrial Fibrillation After TAVR

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

September 01, 2021

News | Left Atrial Appendage (LAA) Occluders

Abbott Amplatzer Amulet LAA Occluder Offers Superior Closure Compared to Watchman

August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) ...

August 31, 2021

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

News | Left Atrial Appendage (LAA) Occluders

FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

August 16, 2021

Schematic illustration of a pre-vascularized stem cell patch having multiple stem cell-laden bio-inks to encorage heart cell regrowth at infarct areas. With permission from Elsevier. Read the original article.Jinah Jang, Reprinted from Biomaterials, Vol 112, Jinah Jang et al., 3D printed complex tissue construct using stem cell-laden decellularized extracellular matrix bioinks for cardiac repair, Pages 264-274, Copyright (2017),

News | Medical 3-D Printing

Bioprinted 3D Cardiac Patches Could Reverse Scar Formation, Promote Myocardial Regeneration After Heart Attacks

July 27, 2021 -- Cardiovascular diseases account for 32% of global deaths. Myocardial infarction, or heart attacks, play ...

July 27, 2021

Leveraging Vivasure Medical’s PerQseal vascular closure device technology, PerQseal Blue consists of an intravascular patch designed to seal the vessel from the inside, returning the vein to its natural state after it dissolves over time, so no foreign bodies are left behind.

News | Vascular Closure Devices

Vivasure Medical is Developing a Sutureless Venous Closure Device for Transcatheter Valve Procedures

July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully ...

July 15, 2021

Videos | Structural Heart

VIDEO: Acurate neo2 TAVR Valve Performs Well in Latest Trials

Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University ...

July 14, 2021

ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.

News | Cath Lab

FDA Clears SafeCross Transseptal RF Puncture and Steerable Balloon Introducer System

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company ...

July 14, 2021

The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.

Feature | Heart Valve Technology

Xeltis Begins Pivotal Trial for Pulmonary Valve That Grows With the Patient

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

July 08, 2021

The balloon inflation to deploy an Edwards Lifesciences Sapien 3 TAVR valve in a failed surgical tricuspid valve. This valve-in-valve (VIV) procedures was performed at Beaumont in a 34-year-old female patient who was determined to be too high of a surgical risk for SAVR.

News | Structural Heart

Beaumont Performs Rare Tricuspid Transcatheter Valve-in-valve Procedure

June 29, 2021 – Cardiologists at Beaumont Health successfully replaced a 34-year-old woman’s tricuspid valve in a rare ...

June 29, 2021

CentraCare completed the first structural heart procedure in the world guided by a new 4-D hologram technology developed by EchoPixel. The augmented reality technology aims to reduce reduce procedure time, improve accuracy of the procedure, and reduce risk of complications.

Feature | Virtual and Augmented Reality

First 4D Hologram Guided Structural Heart Procedure Performed for LAA Occlusion

June 28, 2021 — CentraCare, one of the largest health systems in Minnesota, successfully completed the first structural ...

June 28, 2021

Boston Scientific Makes a Comeback With Positive Clinical Data With its Second Iteration Acurate neo2 TAVR Valve

Blog | Structural Heart

Boston Scientific Makes a Comeback With Positive Clinical Data for its Second Iteration Acurate neo2 TAVR Valve

It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts of ...

June 08, 2021

News | Structural Heart

Edwards LifeSciences Reports Positive Clinical Updates on its Transcatheter Mitral and Tricuspid Valves

June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral and ...

June 07, 2021